Video

Karen Ignagni Calls for Greater Transparency in Pharmaceutical Pricing

No entity in healthcare should have a blank check, but that's the current situation with specialty drugs, said Karen Ignagni, president and chief executive officer of America's Health Insurance Plans.

No entity in healthcare should have a blank check, but that’s the current situation with specialty drugs, said Karen Ignagni, president and chief executive officer of America’s Health Insurance Plans.

Her association has been trying to create a dialogue with pharmaceutical companies to find a way for greater transparency in pricing.

“We want to create sustainable innovation,” she said. “There’s no question. Every American wants that. But at the same time we’re not going to be able to create sustainable innovation unless we have such sustainable pricing.”

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Dr Carrie Kitko
Merrill H. Stewart, MD
Nicolas Ferreyros, managing director, Community Oncology Alliance
Dr Ibrahim Aldoss
Jody Agena, PharmD, MBA, director of pharamcy operations, Virginia Cancer Specialists
Rachel Rohaidy, MD
Mansi Shah, MD
Miriam Freimer, MD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo